Long-Term Results with Adjuvant Ozone Therapy in the Management of Chronic Pelvic Pain Secondary to Cancer Treatment.

" : Funding sources: The publication of this paper and the subsequent randomized clinical trial (EudraCT number: 2019-000821-37, ClinicalTrials.gov: NCT04299893) is supported by a grant (PI 19/00458) from the Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation, Madrid, Spain); a grant (016/2019) from the Fundación DISA (Las Palmas, Spain); and a grant (BF1-19-13), from the Fundación Española del Dolor (Spanish Pain Foundation, Madrid, Spain).: Conflicts of interest: The ozone therapy device Ozonosan Alpha-plus® was provided by Dr. Renate Viebahn (Dr. Hänsler GmbH, Iffezheim, Germany). The authors have no conflicts of interest to disclose.: Trial registration: EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) 2019-000821-37; ClinicalTrials.gov NCT04299893.: Prior presentation: Preliminary data were 1) presented as oral communication at the Second International Traditional and Complementary Medicine Congress (Istanbul, Turkey, April 2019), organized with technical sponsorship of the World Health Organization, and 2) published as a Brief Report in the Journal of Palliative Medicine: Clavo B, Navarro M, Federico M, et al. Ozone therapy in refractory pelvic pain syndromes secondary to cancer treatment: A new approach warranting exploration. J Palliat Med 2020;24(1):97–102."

" : Funding sources: The publication of this paper and the subsequent randomized clinical trial (EudraCT number: 2019-000821-37, ClinicalTrials.gov: NCT04299893) is supported by a grant (PI 19/00458) from the Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation, Madrid, Spain); a grant (016/2019) from the Fundación DISA (Las Palmas, Spain); and a grant (BF1-19-13), from the Fundación Española del Dolor (Spanish Pain Foundation, Madrid, Spain).: Conflicts of interest: The ozone therapy device Ozonosan Alpha-plus® was provided by Dr. Renate Viebahn (Dr. Hänsler GmbH, Iffezheim, Germany). The authors have no conflicts of interest to disclose.: Trial registration: EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) 2019-000821-37; ClinicalTrials.gov NCT04299893.: Prior presentation: Preliminary data were 1) presented as oral communication at the Second International Traditional and Complementary Medicine Congress (Istanbul, Turkey, April 2019), organized with technical sponsorship of the World Health Organization, and 2) published as a Brief Report in the Journal of Palliative Medicine: Clavo B, Navarro M, Federico M, et al. Ozone therapy in refractory pelvic pain syndromes secondary to cancer treatment: A new approach warranting exploration. J Palliat Med 2020;24(1):97–102."